 Fluorouracil
"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 | | 1995 | 1 | 0 | 1 | | 1997 | 1 | 1 | 2 | | 1998 | 0 | 2 | 2 | | 1999 | 2 | 2 | 4 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 2 | 2 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 0 | 4 | 4 | | 2005 | 0 | 1 | 1 | | 2006 | 2 | 3 | 5 | | 2007 | 0 | 2 | 2 | | 2008 | 4 | 4 | 8 | | 2009 | 1 | 4 | 5 | | 2010 | 4 | 5 | 9 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 4 | 4 | | 2013 | 0 | 7 | 7 | | 2014 | 0 | 4 | 4 | | 2015 | 0 | 1 | 1 | | 2016 | 2 | 6 | 8 | | 2017 | 1 | 4 | 5 | | 2018 | 3 | 0 | 3 | | 2019 | 2 | 7 | 9 | | 2020 | 1 | 2 | 3 | | 2021 | 1 | 7 | 8 | | 2022 | 1 | 4 | 5 | | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Young B, Jansen R, Kirk J, Dellavalle R. 5-Fluorouracil toxicosis in our pets: A review and recommendations. J Am Acad Dermatol. 2024 May; 90(5):1051-1052.
-
Pratap A, Qualman A, Garrett H, The E, Chauhan A, Idrovo JP, Cheng L, Wani S, Meguid RA, Meng X. Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells. Anticancer Res. 2023 Aug; 43(8):3411-3418.
-
Azin M, Ameri AH, Nazarian RM, Cusack JC, Tsiaras WG, Asgari MM, Demehri S. Treatment of an Unresectable Cutaneous Squamous Cell Carcinoma With ED&C and 5-FU. Cutis. 2023 07; 112(1):E27-E29.
-
Davis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, Simmons DM, Diamond JR, Lieu CH, Leal AD, Cadogan EB, Hughes GD, Durant ST, Messersmith WA, Pitts TM. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. BMC Cancer. 2022 Oct 29; 22(1):1107.
-
Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park). 2022 10 07; 36(10):604-608.
-
Roy S, Curry SD, Corbella Bagot C, Mueller EN, Mansouri AM, Park W, Cha JN, Goodwin AP. Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles. ACS Nano. 2022 10 25; 16(10):15873-15883.
-
Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, Verheij FS, Omer DM, Lee M, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Paty PB, Weiser MR, Nash GM, Pappou E, Guillem JG, Temple L, Wei IH, Widmar M, Lin S, Segal NH, Cercek A, Yaeger R, Smith JJ, Goodman KA, Wu AJ, Saltz LB. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022 08 10; 40(23):2546-2556.
-
Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? Ann Surg Oncol. 2022 08; 29(8):5051-5052.
-
Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol. 2022 Aug; 29(8):5038-5050.
-
Warfield BM, Reigan P. Multifunctional role of thymidine phosphorylase in cancer. Trends Cancer. 2022 06; 8(6):482-493.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|